Table 2 Estimated probabilities of different endpoints over time in the ATOS study as compared to the ATLG arm of our RCT.
Endpoint | Year | Incidence / rate with 95%-CI | |
|---|---|---|---|
ATOS N = 165 | ATLG (RCT) N = 103 | ||
Severe GvHD and relapse-free survival (SGRFS) | 1 | 0.41 (0.34–0.49) | 0.49 (0.39–0.58) |
5 | 0.27 (0.20–0.34) | 0.34 (0.25–0.43) | |
Acute GvHD any | 1 | 0.56 (0.49–0.64) | 0.56 (0.48–0.67) |
Acute GvHD III-IV | 1 | 0.13 (0.09–0.19) | 0.12 (0.07–0.20) |
Chronic GvHD any | 1 | 0.30 (0.23–0.38) | 0.28 (0.20–0.39) |
5 | 0.42 (0.34–0.51) | 0.31 (0.23–0.42) | |
Chronic GvHD severe | 1 | 0.22 (0.16–0.29) | 0.11 (0.06–0.20) |
5 | 0.27 (0.20–0.35) | 0.14 (0.08–0.23) | |
Relapse | 1 | 0.22 (0.16–0.29) | 0.22 (0.16–0.32) |
5 | 0.34 (0.27–0.42) | 0.35 (0.27–0.46) | |
Non-relapse mortality | 1 | 0.17 (0.12–0.24) | 0.18 (0.12–0.27) |
5 | 0.23 (0.18–0.31) | 0.21 (0.14–0.30) | |
Disease-free survival | 1 | 0.61 (0.54–0.69) | 0.60 (0.51–0.70) |
5 | 0.43 (0.35–0.51) | 0.44 (0.35–0.54) | |
Overall survival | 1 | 0.73 (0.66–0.80) | 0.69 (0.60–0.78) |
5 | 0.52 (0.44–0.60) | 0.50 (0.40–0.60) | |
